Personalized Vaccines for Treating Glioblastoma? Jay Hartenbach & Dr. Will Decker, Diakonos Oncology
In time for the 2026 ASCO Annual Meeting in Chicago, we're highlighting 3 BioTech companies shaping the future of cancer treatment...
On this episode of BioTech Nation, Dr. Will Decker and Jay Hartenbach join Moira to talk about Diakonos Oncology's unique approach to cancer immunotherapy. 25 years ago, as a young post-doc, Dr. Decker made a discovery that wasn't in the biology textbooks - and the scientific community was skeptical. But now, after two decades of research and a new drug entering Phase II human trials for Glioblastoma treatment, that discovery could mean a new pathway to treating aggressive cancers...
On this episode of BioTech Nation, Dr. Will Decker and Jay Hartenbach join Moira to talk about Diakonos Oncology's unique approach to cancer immunotherapy. 25 years ago, as a young post-doc, Dr. Decker made a discovery that wasn't in the biology textbooks - and the scientific community was skeptical. But now, after two decades of research and a new drug entering Phase II human trials for Glioblastoma treatment, that discovery could mean a new pathway to treating aggressive cancers...
